GNLX Genelux Corporation

Subscribe to $GNLX

Genelux Corporation

Subscribe to $GNLX

$GNLX

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year: 2023

Exchange: NASDAQ

Recent Analyst Ratings for Genelux Corporation

Date	Price Target	Rating	Analyst
10/29/2024	$8.00	Buy	Guggenheim
8/28/2024	$10.00	Buy	ROTH MKM
11/27/2023	$35.00	Buy	H.C. Wainwright
9/12/2023	$40.00	Buy	Maxim Group
2/15/2023	$10.00	Speculative Buy	The Benchmark Company

See more ratings

Genelux Corporation SEC Filings

SEC Form 10-Q filed by Genelux Corporation
10-Q - GENELUX Corp (0001231457) (Filer)
5/6/25 4:06:34 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Amendment: SEC Form 10-K/A filed by Genelux Corporation
10-K/A - GENELUX Corp (0001231457) (Filer)
4/29/25 4:05:19 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form S-8 filed by Genelux Corporation
S-8 - GENELUX Corp (0001231457) (Filer)
3/28/25 4:29:17 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 10-K filed by Genelux Corporation
10-K - GENELUX Corp (0001231457) (Filer)
3/28/25 4:05:54 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 424B5 filed by Genelux Corporation
424B5 - GENELUX Corp (0001231457) (Filer)
3/25/25 5:29:56 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Genelux Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - GENELUX Corp (0001231457) (Filer)
3/25/25 5:27:48 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form FWP filed by Genelux Corporation
FWP - GENELUX Corp (0001231457) (Subject)
3/25/25 9:04:44 AM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Genelux Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
8-K - GENELUX Corp (0001231457) (Filer)
3/25/25 9:03:56 AM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Genelux Corporation filed SEC Form 8-K: Financial Statements and Exhibits
8-K - GENELUX Corp (0001231457) (Filer)
2/3/25 6:08:14 AM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
SEC Form 10-Q filed by Genelux Corporation
10-Q - GENELUX Corp (0001231457) (Filer)
11/14/24 4:01:51 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care

Genelux Corporation Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

VP, Clinical Trial Operations Yu Yong sold $16,291 worth of shares (5,579 units at $2.92), decreasing direct ownership by 10% to 47,640 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
5/13/25 5:05:37 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
VP, Pharmaceutical Development Cappello Joseph sold $13,832 worth of shares (4,737 units at $2.92), decreasing direct ownership by 8% to 52,266 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
5/13/25 5:05:36 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
President and CEO Zindrick Thomas sold $31,431 worth of shares (10,764 units at $2.92), decreasing direct ownership by 5% to 191,447 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
5/13/25 5:05:39 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
General Counsel Ryder Sean sold $13,067 worth of shares (4,475 units at $2.92), decreasing direct ownership by 9% to 47,621 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
5/13/25 5:05:41 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Head of Regulatory Smalling Ralph sold $3,676 worth of shares (1,259 units at $2.92), decreasing direct ownership by 3% to 34,760 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
5/13/25 5:05:32 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
Head of Regulatory Smalling Ralph was granted 4,172 shares, increasing direct ownership by 13% to 36,019 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
4/17/25 4:58:47 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
VP, Pharmaceutical Development Cappello Joseph was granted 13,350 shares, increasing direct ownership by 31% to 57,003 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
4/17/25 4:57:32 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
VP, Clinical Trial Operations Yu Yong was granted 13,350 shares, increasing direct ownership by 33% to 53,219 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
4/17/25 4:56:26 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
General Counsel Ryder Sean was granted 10,708 shares, increasing direct ownership by 26% to 52,096 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
4/17/25 4:55:20 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care
President and CEO Zindrick Thomas was granted 30,339 shares, increasing direct ownership by 18% to 202,211 units (SEC Form 4)
4 - GENELUX Corp (0001231457) (Issuer)
4/17/25 4:54:13 PM ET
$GNLX
Biotechnology: Pharmaceutical Preparations
Health Care

Genelux Corporation

Recent Analyst Ratings for Genelux Corporation

Genelux Corporation SEC Filings

SEC Form 10-Q filed by Genelux Corporation

Amendment: SEC Form 10-K/A filed by Genelux Corporation

SEC Form S-8 filed by Genelux Corporation

SEC Form 10-K filed by Genelux Corporation

SEC Form 424B5 filed by Genelux Corporation

Genelux Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form FWP filed by Genelux Corporation

Genelux Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

Genelux Corporation filed SEC Form 8-K: Financial Statements and Exhibits

SEC Form 10-Q filed by Genelux Corporation

Genelux Corporation Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

VP, Clinical Trial Operations Yu Yong sold $16,291 worth of shares (5,579 units at $2.92), decreasing direct ownership by 10% to 47,640 units (SEC Form 4)

VP, Pharmaceutical Development Cappello Joseph sold $13,832 worth of shares (4,737 units at $2.92), decreasing direct ownership by 8% to 52,266 units (SEC Form 4)

President and CEO Zindrick Thomas sold $31,431 worth of shares (10,764 units at $2.92), decreasing direct ownership by 5% to 191,447 units (SEC Form 4)

General Counsel Ryder Sean sold $13,067 worth of shares (4,475 units at $2.92), decreasing direct ownership by 9% to 47,621 units (SEC Form 4)

Head of Regulatory Smalling Ralph sold $3,676 worth of shares (1,259 units at $2.92), decreasing direct ownership by 3% to 34,760 units (SEC Form 4)

Head of Regulatory Smalling Ralph was granted 4,172 shares, increasing direct ownership by 13% to 36,019 units (SEC Form 4)

VP, Pharmaceutical Development Cappello Joseph was granted 13,350 shares, increasing direct ownership by 31% to 57,003 units (SEC Form 4)

VP, Clinical Trial Operations Yu Yong was granted 13,350 shares, increasing direct ownership by 33% to 53,219 units (SEC Form 4)

General Counsel Ryder Sean was granted 10,708 shares, increasing direct ownership by 26% to 52,096 units (SEC Form 4)

President and CEO Zindrick Thomas was granted 30,339 shares, increasing direct ownership by 18% to 202,211 units (SEC Form 4)